Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007 Feb 20; 25(6):634-41.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.